Reading the tape
AMEX: SER
Serina Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$17.50M
52w High
$7.92
52w Low
$1.22
P/E
-0.93
Volume
39.64K
Outstanding Shares
10.00M
Price vs Fundamentals
Why The Stock Is Moving
Likely multiple compressionModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -69.57%Revenue (TTM): 2,500%FCF (TTM): -4.71%
What changed
The stock fell 69.57% over the last year. Revenue grew 2,500% over the trailing twelve months. Operating margin moved from -340,960% to -18,478.46%. Free cash flow declined 4.71% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently -18,478.46%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Company profile
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain.
CEOSteven A. Ledger
SectorHealthcare
IndustryBiotechnology
Employees12
IPO dateJan 21, 2000
Valuation
Forward P/E—
EV/EBITDA-0.69
Enterprise value$16.6M
Stock splits
Mar 15, 2024↓ Reverse
Every 250 shares became 7
Profitability & growth
Revenue growth-100%
Gross margin43.85%▲114.05%vs FY2024
Operating margin-18,478.46%▲39.30%vs FY2024
ROE51,843.24%▲3082.81%vs FY2024
Analyst consensus
RatingBuy
Target price—
1
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 19, 2026
Q2 FY26 · EPS est -$0.44 · Revenue est —
View